Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma

Leukemia and Lymphoma

Volumn 52, Issue SUPPL. 3, 2011, Pages 1-14

  López Guillermo, Armando ^a   Caballero, Dolores ^b   Canales, Miguel ^c   Provencio, Mariano ^d   Rueda, Antonio ^e   Salar, Antonio ^f  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^e HOSPITAL COSTA DEL SOL   (Spain)

^f HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; INTERFERON; MITOXANTRONE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ARTICLE; BIOPSY TECHNIQUE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CLINICAL PRACTICE; FOLLICULAR LYMPHOMA; FOLLOW UP; HEALTH CARE PERSONNEL; HUMAN; IMAGE ANALYSIS; LABORATORY TEST; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; TREATMENT OUTCOME;

HUMANS; LYMPHOMA, FOLLICULAR; RECURRENCE;

EID: 83455210407     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.629897     Document Type: Article

References (49)

1. H arris NL, Swerdlow SH, Jaff e ES, et al. Follicular lymphoma. In: Swerdlow SH, Campo E, Harris NL, editors. WHO classifi cation of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp. 220-226.
2. Dreyling M. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and followup. Ann Oncol 2009;20(Suppl. 4):119-120.
3. Curado MP, Edwards B, Shin HR, et al., editors. Cancer incidence in fi ve continents. Vol. IX. Lyon: IARC; 2009.
4. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555-4562.
5. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-1265. (Pubitemid 39166497)
6. Arcaini L, Merli M, Passamonti F, et al. Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. Br J Haematol 2010;149:455-457.
7. Scottish Intercollegiate Guidelines Network. SIGN 50: A guideline developer ' s handbook. Revised ed. Edinburgh: SIGN; 2008.
8. Grupo de trabajo sobre GPC. Elaboración de Guías de Prá ctica Cl ínica en el Sistema Nacional de Salud. Manual Metodológico. Gu ías de Pr á ctica Cl ínica en el SNS: I - CS No 2006/0I. Madrid: Plan Nacional para el SNS del MSC. Instituto Aragon é s de Ciencias de la Salud-I - CS; 2007.
9. Ardeshna KM, Smith P, Norton A, et al. Long-term eff ect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003;362:516-522. (Pubitemid 36976715)
10. Horning SJ, Rosenberg SA. Th e natural history of initially untreated low-grade non-Hodgkin ' s lymphomas. N Engl J Med 1984;311: 1471-1475. (Pubitemid 15211022)
11. Solal-Celigny P, Lepage E, Brousse N, et al. Doxorubicincontaining regimen with or without interferon alfa-2b for advanced follicular lymphomas: fi nal analysis of survival and toxicity in the Groupe d ' Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol 1998;16:2332-2338. (Pubitemid 28309024)
12. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumorburden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d ' Etude des Lymphomes Folliculaires. Groupe d ' Etude des Lymphomes de l ' Adulte. J Clin Oncol 1997;15:1110-1117. (Pubitemid 27106296)
13. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single fi rst-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001;97:101-106. (Pubitemid 32061248)
14. Colombat P, Salles G, Brousse N, et al. Single treatment with rituximab monotherapy for low tumor burden follicular lymphoma (FL): survival analyses with extended follow-up of 7 years. Blood 2006;108(Suppl. 1): Abstract 486.
15. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352: 441-449. (Pubitemid 40175970)
16. Ardeshna KM, Qian W, Smith P, et al. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis. Blood 2010;116(Suppl. 1): Abstract 6.
17. MacManus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term followup study of patients treated at Stanford University. J Clin Oncol 1996; 14:1282-1290. (Pubitemid 26105537)
18. Campbell BA, Voss N, Woods R, et al. Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer 2010;116: 3797-3806.
19. Heinzelmann F, Engelhard M, Ottinger H, et al. Nodal follicular lymphoma: the role of radiotherapy for stages I and II. Strahlenther Onkol 2010;186:191-196.
20. Herold M, Haas A, Srock S, et al. Rituximab added to fi rstline mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:1986-1992. (Pubitemid 46972781)
21. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) signifi cantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-3732. (Pubitemid 41742196)
22. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579-4586.
23. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as fi rst-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-1423. (Pubitemid 40223656)
24. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008;112: 4824-4831.
25. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is eff ective and has a favorable toxicity profi le in the treatment of mantle cell and low-grade non-Hodgkin ' s lymphoma. J Clin Oncol 2005;23:3383-3389.
26. Rummel MJ, Niederle N, Maschmeyer G. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as fi rst-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: fi nal results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009; 114(Suppl. 1): Abstract 405.
27. Cheson BD, Pfi stner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586. (Pubitemid 350002966)
28. Cheson BD, Horning SJ, Coiffi er B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin ' s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
29. Gonzalez H, Cazaentre T. [90Y-ibritumomab tiuxetan (Zevalin) consolidation of fi rst remission in advanced stage follicular non-Hodgkin' s lymphoma: fi rst results of the international randomized phase 3 fi rst-line trial (FIT) in 414 patients]. Med Nucl 2008;32(Suppl. 1):S1-S7. [in French]
30. Rohatiner AZ, Gregory WM, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005;23:2215-2223. (Pubitemid 46218713)
31. Ghielmini M, Schmitz SFH, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma signifi cantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004 15;103:4416-4423. (Pubitemid 38745964)
32. Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol 2009;27: 1607-1614.
33. Salles G, Seymour JF, Off ner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:42-51.
34. Deconinck E, Foussard C, Milpied N, et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 2005;105:3817-3823. (Pubitemid 40656123)
35. Gyan E, Foussard C, Bertrand P, et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicinbased chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with fi nal results after a median follow-up of 9 years. Blood 2009;113:995-1001.
36. Lenz G, Dreyling M, Schiegnitz E, et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in fi rst remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004;104:2667-2674. (Pubitemid 39434946)
37. Sebban C, Mounier N, Brousse N, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d ' Etude des Lymphomes de l ' Adulte (GELA). Blood 2006;108:2540-2544.
38. Ladetto M, De Marco F, Benedetti F, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008;111: 4004-4013.
39. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833. (Pubitemid 28363048)
40. Czuczman MS, Weaver R, Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin ' s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22:4711-4716.
41. Forstpointner R, Dreyling M, Repp R, et al. Th e addition of rituximab to a combination of fl udarabine, cyclophosphamide, mitoxantrone (FCM) signifi cantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064-3071. (Pubitemid 39517009)
42. Van Oers MHJ, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295-3301. (Pubitemid 44794222)
43. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a signifi cant prolongation of response duration after salvage therapy with a combination of rituximab, fl udarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108: 4003-4008. (Pubitemid 44920177)
44. Van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin ' s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010;28:2853-2858.
45. Vidal L, Gafter-Gvili A, Leibovici L, et al. Rituximab as maintenance therapy for patients with follicular lymphoma. Cochrane Database Syst Rev 2009;(2):CD006552.
46. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin ' s lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003;21:3918-3927. (Pubitemid 46606204)
47. Schuster SJ, Neelapu SS, Gause BL, et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in fi rst complete remission: phase III clinical trial results. J Clin Oncol 2009;27(18 Suppl.): Abstract 2.
48. Ai WZ, Tibshirani R, Taidi B, et al. Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood 2009;113:5743-5746.
49. Freedman A, Neelapu SS, Nichols C, et al. Placebocontrolled phase III trial of patient-specifi c immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol 2009;27:3036-3043.